University of California (Irvine) Hematology and Medical Oncology

Topics

• Chronic Lymphocytic Leukemia Research 469
• Chronic Myeloid Leukemia Treatments 328
• Acute Myeloid Leukemia Research 280
• Lung Cancer Treatments and Mutations 150
• Acute Lymphoblastic Leukemia research 134
• Hematopoietic Stem Cell Transplantation 111
• Lymphoma Diagnosis and Treatment 94
• Myeloproliferative Neoplasms: Diagnosis and Treatment 85
• Cancer Immunotherapy and Biomarkers 64
• Cancer Genomics and Diagnostics 55
• Bladder and Urothelial Cancer Treatments 54
• Pancreatic and Hepatic Oncology Research 44

Most cited

1. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.

   The New England journal of medicine · 2024 · 923 citations · Nataliya Mar

2. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

   The New England journal of medicine · 2023 · 739 citations · Warren Chow

3. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

   The New England journal of medicine · 2022 · 868 citations · Misako Nagasaka

4. Acquired Resistance to KRASG12C Inhibition in Cancer.

   The New England journal of medicine · 2021 · 1,038 citations · Shannon Zhang

5. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.

   The New England journal of medicine · 2023 · 435 citations · Susan O'Brien

6. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

   Journal of the National Comprehensive Cancer Network : JNCCN · 2021 · 587 citations · Mihaela Cristea

7. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.